You are here

Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
New Haven, Connecticut, 06511 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Erectile Dysfunction
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Healthy males between the ages of 18 and 55 years. Body Mass Index of 18 to 30 kg/m2, and a
total body weight >50 kg (110 lbs).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Smoking in excess of the equivalent of 5 cigarettes per day. Treatment with an experimental
drug within 30 days or sildenafil, vardenafil, tadalfil within 4 days before first study
dose.

Develop blood pressure lowering or experience dizziness, lightheadedness when going from
the laying down position to standing position.

NCT00795938
Pfizer
Completed
Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Solid Tumor Neoplasms
NCT00037804
All Genders
18+
Years
Multiple Sites
Erectile Dysfunction
NCT00648596
Males
18+
Years
Multiple Sites
Spinal Cord Injury, Erectile Dysfunction, Spinal Cord Trauma, Spinal Cord Injuries, Impotence
NCT00654082
Males
19+
Years
Multiple Sites
Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.
An Open-Label, Crossover Study In Healthy Volunteers To Evaluate The Pharmacokinetics Of Sildenafil Following Administration Of An Experimental Tablet Of Sildenafil With Or Without Water Relative To Viagra® Conventional Oral Tablet With Water.
This study to will compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Erectile Dysfunction
  • Drug: Sildenafil
    Single Dose of 50 mg Sildenafil Oral Tablet With Water
  • Drug: Sildenafil
    Single Dose of 50 mg Sildenafil Experimental Tablet With Water
  • Drug: Sildenafil
    Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
  • Active Comparator: Conventional Oral Tablet With Water
    Intervention: Drug: Sildenafil
  • Experimental: Experimental Tablet With Water
    Intervention: Drug: Sildenafil
  • Experimental: Experimental Tablet Without Water
    Intervention: Drug: Sildenafil
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
November 2008
November 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Healthy males between the ages of 18 and 55 years. Body Mass Index of 18 to 30 kg/m2, and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

Smoking in excess of the equivalent of 5 cigarettes per day. Treatment with an experimental drug within 30 days or sildenafil, vardenafil, tadalfil within 4 days before first study dose.

Develop blood pressure lowering or experience dizziness, lightheadedness when going from the laying down position to standing position.

Sexes Eligible for Study: Male
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00795938
A1481266
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now